Ignite Creation Date:
2025-12-24 @ 10:37 PM
Ignite Modification Date:
2026-01-01 @ 7:41 AM
Study NCT ID:
NCT01747135
Status:
COMPLETED
Last Update Posted:
2021-07-23
First Post:
2012-12-08
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Hydroxypropyl Beta Cyclodextrin for Niemann-Pick Type C1 Disease
Sponsor:
Vtesse, LLC, a Mallinckrodt Pharmaceuticals Company
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2013-01
Start Date Type:
None
Primary Completion Date:
2017-03
Primary Completion Date Type:
ACTUAL
Completion Date:
2017-03
Completion Date Type:
ACTUAL
First Submit Date:
2012-12-08
First Submit QC Date:
None
Study First Post Date:
2012-12-11
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-07-19
Last Update Post Date:
2021-07-23
Last Update Post Date Type:
ACTUAL